Ashwagandha is not considered safe to take while breastfeeding. No human studies have tested its effects on nursing infants, and the active compounds in the herb have properties that raise real concerns about what could pass through breast milk. Most medical and herbal safety databases classify ashwagandha as contraindicated during lactation, and that guidance has not changed as the supplement has grown more popular.
Why the Safety Data Does Not Exist
The core problem is straightforward: researchers have never conducted a controlled trial giving ashwagandha to breastfeeding women and monitoring their infants. Ethical review boards are unlikely to approve such a study because the potential risks to a developing infant outweigh the benefits of testing a supplement that is not medically necessary. This is not unusual for herbal products. Most botanical supplements lack lactation-specific safety data, and ashwagandha is no exception. What sets it apart is that the pharmacological activity of its key compounds gives specific, identifiable reasons for caution rather than just a vague “we don’t know.”
Without direct evidence, safety recommendations rely on what we know about ashwagandha’s active compounds, how they behave in adults, and general principles of how substances move into breast milk. That indirect picture is not reassuring.
How Maternal Substances Reach a Nursing Infant
Compounds from a mother’s diet routinely transfer into breast milk. A systematic review found moderate evidence that flavors from foods like garlic, carrot, mint, and other dietary components show up in breast milk within hours of a single ingestion, and infants can detect those transmitted flavors.1The American Journal of Clinical Nutrition. Influence of maternal diet on flavor transfer to amniotic fluid and breast milk and children’s responses: a systematic review If simple food flavors pass through that quickly, bioactive plant alkaloids, steroidal lactones, and other pharmacologically active molecules in ashwagandha are plausibly transferable as well. The question is not whether something gets into the milk. The question is what that something does once the infant ingests it.
The GABAergic Concern
Ashwagandha’s calming and sleep-promoting effects are part of why people take it, but the mechanism behind those effects is exactly what makes it worrying for a nursing baby. Research shows that ashwagandha works partly through the same brain signaling system targeted by sedatives and anti-anxiety drugs. A review of the evidence found that the herb modulates the body’s stress-response pathways and also acts through GABA and serotonin signaling in the brain.2PubMed Central. Effects of Withania somnifera (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia
Laboratory work has confirmed this directly. Aqueous extracts of ashwagandha activate GABA receptors on nerve cells, with one particular receptor subtype being about 27 times more sensitive to the extract than another.3Journal of Ethnopharmacology. Direct evidence for GABAergic activity of Withania somnifera on mammalian ionotropic GABAA and GABAρ receptors GABA is the brain’s main inhibitory neurotransmitter. In adults, boosting GABA activity produces relaxation and drowsiness. In a newborn or young infant whose nervous system is still developing rapidly, the effects of an external GABA-activating compound are unpredictable. An infant’s blood-brain barrier, liver metabolism, and kidney clearance all function differently from an adult’s, meaning even small amounts of a neuroactive substance could have outsized effects.
Liver Injury in Otherwise Healthy Adults
Even setting aside the infant, ashwagandha carries risks for the mother that become more concerning during the postpartum period. A systematic review of case reports identified 26 patients who developed liver injury linked to ashwagandha use. The average age was about 38, and over half were male, but the pattern of injury was consistent across cases: jaundice appeared in roughly nine out of ten patients, and itching in about three-quarters. Most patients recovered after stopping the supplement, but severe cases required intensive care or liver transplantation.4The Egyptian Journal of Internal Medicine. Ashwagandha-induced liver injury: a systematic review of case reports
Some cases developed remarkably fast. One report described a previously healthy 27-year-old woman who developed jaundice and widespread itching after taking ashwagandha for just three days. Her liver biopsy showed a cholestatic pattern of injury, and a formal causality assessment scored the connection to ashwagandha as “probable.”5PubMed Central. Ashwagandha-Induced Herb-Induced Liver Injury Assessed With the Updated 2016 RUCAM Another case involved a man who had been taking the supplement for a year before developing acute hepatitis with elevated liver enzymes across the board.6PubMed Central. Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury
For a breastfeeding mother, liver damage is a compounding risk. The postpartum body is already recovering from pregnancy, sleep deprivation strains metabolic processes, and any impairment of liver function could affect the composition and safety of breast milk itself. A mother who develops drug-induced liver injury also faces potential interruptions in breastfeeding if hospitalization becomes necessary.
Contamination Makes the Risk Worse
Even if ashwagandha’s own active compounds were proven harmless during lactation, the supplement itself might not be. Herbal supplements are not regulated the way pharmaceuticals are, and contamination is a documented problem across the industry.
A study testing adaptogenic herbal supplements, including ashwagandha products, found widespread heavy metal contamination. In processed forms like tablets and dried preparations, lead concentrations exceeded permissible limits by up to 235 percent, and nickel levels were exceeded by up to 321 percent.7PubMed Central. Heavy Metal Contamination in Adaptogenic Herbal Dietary Supplements: Experimental, Assessment and Regulatory Safety Perspectives Lead is a well-established neurotoxin with no safe level of exposure for infants. Even tiny amounts of lead transferred through breast milk could contribute to developmental harm.
The problem extends beyond ashwagandha. A review of prenatal and postpartum supplements more broadly found that somewhere between 18 and 40 percent of commercially available products contain undeclared pharmaceuticals, heavy metals, or incorrect dosages.8PubMed Central. Dietary Supplements in Pregnancy and Postpartum: Evidence, Safety Challenges and a Precision Nutrition Framework (GAPSS) When you take an unregulated supplement while breastfeeding, you are not just deciding to take ashwagandha. You are trusting that the manufacturer accurately labeled the product, excluded contaminants, and delivered the dose claimed on the bottle. That trust is frequently misplaced.
Root Versus Whole-Plant Products
Not all ashwagandha products are created equal, and this matters for understanding the risk profile. A comprehensive safety evaluation using data from multiple studies found that ashwagandha root has a meaningfully better safety profile than non-root parts of the plant, particularly when it comes to liver and reproductive toxicity. The root compared favorably to many other herbal supplements, while non-root parts showed higher toxicity potential.9PubMed Central. Comprehensive safety evaluation of Withania somnifera (Ashwagandha): an AI-driven meta-analysis and quantitative structure–activity relationship based toxicity assessment
This distinction rarely shows up on supplement labels in a way that helps the consumer. Some products use root extract exclusively, others blend root with leaf or whole-plant material, and many do not specify clearly. The leaves and aerial parts of the plant contain different concentrations of active compounds, including withanolides that may behave differently from those concentrated in the root. For a breastfeeding mother trying to assess risk, this variability makes an already uncertain situation even harder to navigate. Even “root-only” products can vary substantially in their withanolide content depending on extraction method and standardization practices.
The Postpartum Stress Paradox
The irony is that the reason many new mothers consider ashwagandha is real and well-documented. Postpartum stress, anxiety, and fatigue are common, and the appeal of a “natural” remedy that could take the edge off without a prescription is understandable. The evidence that ashwagandha reduces stress in the general adult population is actually fairly strong. A systematic review and meta-analysis found that supplementation significantly reduced anxiety scores, perceived stress, and cortisol levels compared to placebo over eight weeks of treatment.10PubMed Central. Effects of Ashwagandha Supplements on Cortisol, Stress, and Anxiety Levels in Adults: A Systematic Review and Meta-Analysis
Those results are compelling for a stressed-out new parent scanning the supplement aisle. But every one of those trials excluded pregnant and breastfeeding women. The findings apply to healthy, non-lactating adults. Extrapolating them to a breastfeeding mother who is also sharing her biochemistry with an infant through milk is a leap the data does not support. The same GABAergic and cortisol-lowering mechanisms that make ashwagandha effective for adult stress are the mechanisms that pose the greatest theoretical risk to a developing infant’s brain.
What You Can Do Instead
If postpartum anxiety or stress is the issue driving interest in ashwagandha, there are options with better safety profiles during breastfeeding. The most evidence-backed approaches are not supplements at all. Cognitive behavioral therapy has strong evidence for postpartum anxiety and depression and carries zero risk to the infant. Physical activity, even modest amounts, reliably reduces stress hormones and improves mood in postpartum women. Structured relaxation techniques have also shown promise: one study found that guided imagery reduced both fatigue and anxiety scores significantly within just three days postpartum compared to a control group.11Care : Jurnal Ilmiah Ilmu Kesehatan. Islamic Guided Imagery for Reducing Postpartum Fatigue and Anxiety: Development of Midwifery Care
For mothers who want a supplement specifically, certain options have more established safety data during lactation. Magnesium glycinate, for example, is commonly used for stress and sleep support and is generally considered compatible with breastfeeding at standard doses. Some herbal teas, like chamomile in moderate amounts, have longer histories of use during lactation, though even these lack rigorous trial data. The honest reality is that very few supplements of any kind have been rigorously tested in breastfeeding populations. When postpartum anxiety is severe enough to consider self-treating with supplements, it is often severe enough to warrant a conversation with a healthcare provider about prescription options that have actually been studied in lactating women, such as certain SSRIs.
When Could You Start Again
If you were taking ashwagandha before or during pregnancy and want to resume, the question becomes about timing. Most guidance suggests waiting until breastfeeding has ended entirely. If you are combination feeding (breast milk plus formula), the risk does not disappear but is diluted in proportion to how much breast milk the infant receives. There is no established “safe” washout period during active breastfeeding because nobody has measured ashwagandha metabolite levels in breast milk over time.
Once your child is fully weaned and no longer receiving any breast milk, the considerations shift back to your own adult health profile. At that point, the liver injury risk, contamination concerns, and drug interaction potential still apply to you personally, but the infant is no longer in the equation. If you do resume, choosing a third-party-tested, root-only extract from a reputable manufacturer reduces, though does not eliminate, the contamination and potency variability issues. Starting at a low dose and monitoring how you feel over several weeks is a more cautious approach than jumping to the high end of supplement-label recommendations.
Thyroid Effects and Medication Interactions
One additional concern that breastfeeding mothers may not be aware of is ashwagandha’s effect on thyroid function. The herb has been associated with increases in thyroid hormone levels, and case reports have documented thyrotoxicosis in people taking standard supplement doses. Postpartum thyroiditis already affects a meaningful percentage of women in the months after delivery, and adding a thyroid-stimulating supplement to an already fluctuating hormonal landscape could mask or worsen thyroid problems at a time when they are more likely to occur naturally.
If you are taking thyroid medication, blood pressure medication, diabetes medication, immunosuppressants, or sedatives, ashwagandha can interact with all of these. The GABAergic activity described earlier means combining it with benzodiazepines, sleep aids, or even antihistamines that cause drowsiness could amplify sedation. For a breastfeeding mother who may already be sleep-deprived and taking other medications, adding an unregulated supplement with multiple drug interaction pathways adds complexity that most healthcare providers would advise against.
Reading Supplement Labels During Lactation
Ashwagandha products marketed as “safe for new moms” or “postpartum support” formulations are increasingly common online. These marketing claims are not evaluated by regulatory agencies before the product goes to market. In most countries, supplement manufacturers are responsible for ensuring their own products are safe, but they are not required to prove safety before selling. This is the opposite of how pharmaceutical drugs work, where safety must be demonstrated before approval.
Some red flags to watch for on ashwagandha supplement labels include proprietary blends that do not disclose the amount of ashwagandha per serving, the absence of third-party testing seals, inclusion of non-root plant parts without clear labeling, and dosages that vary dramatically from what has been used in clinical research (typically 300 to 600 milligrams of root extract daily in adult studies). Products listing withanolide content as a standardized percentage are at least attempting quality control, but even this does not guarantee the absence of contaminants or confirm safety during lactation.